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Background: Components of the innate immune complement system have been implicated in the pathogenesis
of amyotrophic lateral sclerosis (ALS); however, a comprehensive examination of complement expression in this
disease has not been performed. This study therefore aimed to determine the expression of complement components
(C1qB, C4, factor B, C3/C3b, C5 and CD88) and regulators (CD55 and CD59a) in the lumbar spinal cord of hSOD1G93A
mice during defined disease stages.
Methods: hSOD1G93A and wild-type mice were examined at four different ages of disease progression. mRNA and
protein expression of complement components and regulators were examined using quantitative PCR, western
blotting and ELISA. Localisation of complement components within lumbar spinal cord was investigated using
immunohistochemistry. Statistical differences between hSOD1G93A and wild-type mice were analysed using a two-tailed
t-test at each stage of disease progression.
Results: We found several early complement factors increased as disease progressed, whilst complement regulators
decreased; suggesting overall increased complement activation through the classical or alternative pathways in
hSOD1G93A mice. CD88 was also increased during disease progression, with immunolocalisation demonstrating
expression on motor neurons and increasing expression on microglia surrounding the regions of motor neuron death.
Conclusions: These results indicate that local complement activation and increased expression of CD88 may contribute
to motor neuron death and ALS pathology in the hSOD1G93A mouse. Hence, reducing complement-induced
inflammation could be an important therapeutic strategy to treat ALS.
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Amyotrophic lateral sclerosis (ALS) is a late-onset neuro-
degenerative disorder characterised by selective loss of
upper motor neurons within the motor cortex, and of α-
motor neurons of the spinal cord and brainstem [1]. This
results in symptoms of muscle weakness and atrophy of
skeletal muscles, leading to paralysis and eventual death
due to failure of respiratory muscles [2]. The mechanisms* Correspondence: t.woodruff@uq.edu.au; p.noakes@uq.edu.au
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reproduction in any medium, provided the orleading to ALS are still unclear but there are compelling
data that suggest neuroinflammation may contribute to the
disease progression of ALS [1,3,4]. These data include the
presence of reactive microglia and astrocytes, infiltration of
T lymphocytes and upregulation of cyclooxygenase 2 and
prostaglandin E2 in the spinal cord of ALS patients and
animal models [5-9]. The classical complement system is
also implicated in ALS pathology, as studies have shown
activation fragments of complement components C1q, C3
and C4 are increased in the serum, cerebrospinal fluid and
neurological tissue (including spinal cord and motor
cortex) of ALS patients [4].
In addition to evidence suggesting complement in-
volvement in human ALS pathology, several studies have. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Different stages defined in amyotrophic lateral
sclerosis
Stage Age Phenotype
Pre-symptomatic 30 days postnatal No signs of motor deficit
Onset 70 days postnatal Initial signs of motor deficit
(grip strength)
Mid-symptomatic 130 days postnatal Weakness in hind-limb and tremor
when suspended by the tail
End 150 to 175 days
postnatal
Full paralysis of lower limbs and
loss of righting reflex
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in animal models of ALS. Upregulation of the classical
pathway complement components C1q and C4, as well
as of the central factor C3, has been shown in human
SOD1 transgenic rodent models of ALS [4]. Other studies
have also shown upregulation of the major proinflam-
matory C5a receptor, CD88, during disease progression
[10,11]. In addition, our group has shown that chronic ad-
ministration of a specific CD88 antagonist in hSOD1G93A
transgenic rats delayed the onset of motor symptoms and
increased survival compared with untreated animals [11].
Overall, these studies indicate that overactivation of the
complement system and increased C5a-CD88 signalling
contribute to the progression of disease in these animal
models of ALS.
In the present study, we examined the expression
and cellular location of major complement factors and
regulators during defined disease stages in hSOD1G93A
mice in order to provide a comprehensive overview of
complement’s involvement in ALS. Additionally, given
the importance of C5a in disease pathology in ALS
models [10,11], we also examined mRNA, protein levels,
and the cellular localisation of C5, C5a and its cognate
receptor, CD88, during disease progression. Our find-
ings demonstrate a global dysregulation of complement,




All experimental procedures were approved by the
University of Queensland Animal Ethics Committee (Per-
mit Number: 227–09), and complied with the policies and
regulations regarding animal experimentation and other
ethical matters [12]. They were conducted in accordance
with the Queensland Government Animal Research Act
2001, associated Animal Care and Protection Regulations
(2002 and 2008), and the Australian Code of Practice for
the Care and Use of Animals for Scientific Purposes, 7th
Edition (National Health and Medical Research Council,
2004). ARRIVE guidelines have been followed in the prep-
aration of the manuscript.
Animals
Transgenic hSOD1G93A mice (B6-Cg-Tg (SOD1-G93A)
1Gur/J) were obtained from Jackson Laboratory (Bar
Harbor, ME, USA) and were bred on a C57BL/6J back-
ground to produce hSOD1G93A mice and wild-type (WT)
control mice. These hSOD1G93A mice carry a high copy
number of the mutated allele of the human (h) SOD1 gene.
Female hSOD1G93A and WT mice at four predefined stages
of ALS were used in this study (Table 1). By the end stage
of ALS, hSOD1G93A mice display significant signs of hind-
limb weakness, paralysis and loss of the righting reflex. Allmice were anaesthetised with intraperitoneal injection of
zolazapam (50 mg/kg, Zoletil; Lyppard, Melbourne, VIC,
Australia) and xylazine (10 mg/kg, Xylazil; Lyppard) prior
to the collection of tissue samples.
Weight measurements and behavioural tests
hSOD1G93A and WT mice were weighed weekly at the
same time of day (4:00 p.m.), from 42 days of age until
end-stage when they lose their righting reflex. Two
neuromotor tests, the Rota-rod and hind-limb grip
strength test, were conducted on hSOD1G93A and age-
matched WT mice (detailed below). These tests were
performed blinded to genotype.
Rota-rod test
Mice were tested for their motor coordination from
42 days of age using Rota-rod apparatus (Ugo Basile,
Comerio, VA,Italy) at a constant speed of 20 rpm. Each
mouse was given three attempts and the longest latency
to fall was recorded; 180 seconds was chosen as the arbi-
trary cutoff time. One week prior to the test, mice were
trained twice to remain on the Rota-rod apparatus to ex-
clude differences in motivation and motor learning. In
the training phase, mice were placed on the Rota-rod at a
constant speed of 20 rpm for a maximum duration of
240 seconds [13].
Hind-limb grip strength test
A digital force gauge (Ugo Basile) was used to measure
maximal muscle grip strength. The mice were held by
their tail and lowered until the mice grasped the T-bar
connected to the digital force gauge with their hind
limbs. The tail is lowered until the body is horizontal
and the mice are pulled away from the T-bar with a
smooth steady pull until both of their hind limbs re-
leased the bar. The strength of the grip was measured in
gram force. Each mouse was given 10 attempts and the
maximum grip strength was recorded.
Immunohistochemistry
hSOD1G93A and WT mice were fixed by transcardiac
perfusion with 2% sodium nitrite buffer (Ajax Finechem
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paraformaldehyde (Sigma, St. Louis, MO, USA) in 0.1 M
phosphate buffer pH 7.4. The lumbar spinal cords were
collected and then placed in 4% paraformaldehyde for
another 2 hours at 4°C. The lumbar spinal cords were
embedded in optimal cutting temperature compound
(Sakura Finetek, Torrance, CA, USA,) and snap frozen
in liquid nitrogen. Serial transverse cryosections (16 μm)
were collected on Superfrostplus slides (Menzel-Glaser,
Braunschweig, Germany) for estimation of motor neuron
numbers and fluorescence immunohistochemistry.
For the motor neuron numbers in the spinal cord, the
sections are stained using 0.1% thionin (v/v) in acetic
acid buffer solution (Sigma) for 3 minutes and processed
as per our previous studies [14]. The lumbar lateral
motor column extending from the second lumbar dor-
sal root ganglia to the sixth lumbar dorsal root ganglia
was selected from our serial spinal sections, with the
aid of the mouse spinal cord atlas [15]. Alpha-motor
neurons within the lumbar lateral motor column were
identified and counted on both sides of the spinal cord
in every 10th section following previous guidelines [16-18].
The mouse genotypes were not made available to the
researcher (JDL) conducting the counts until it was
completed.
Fluorescence double-labelling was performed to local-
ise the expression of C1q, C3b, C5 and its receptor
CD88 with specific cell-type markers for motor neurons,
astrocytes and microglia. All sections were rehydrated in
PBS pH 7.4 and blocked in PBS containing 3% bovine
serum albumin (BSA) or 3% donkey serum and 1% BSA
for 1 hour at room temperature. Sections were then in-
cubated overnight at 4°C with a combination of anti-
bodies outlined in Table 2. All primary antibodies were
diluted in PBS containing 1% BSA or 1% donkey serum.
These sections were then washed 3× 10 minutes with
PBS prior to incubation with an appropriate Alexa conju-
gated secondary cocktail: Alexa 555 goat anti-rat, Alexa
555 goat anti-mouse, Alexa 594 donkey anti-rat, Alexa 555Table 2 Summary of antibodies used for immunohistochemis
Antibody Manufacturer
Rat anti-mouse C1q Hycult Biotechnology1
Rat anti-mouse C3b Hycult Biotechnology1
Mouse anti-mouse C5 Hycult Biotechnology1
Rat anti-mouse CD88 AbD Serotec2
Mouse anti-mouse GFAP BD Biosciences3
Rabbit anti-mouse Iba-1 Wako4
Rat anti-mouse CD11b Abcam5
Goat anti-mouse ChAT Chemicon6
GFAP, glial fibrillary acidic protein; ChAT, choline acetyltransferase; Iba-1, ionized calciu
Serotec; 3 BD Biosciences, Sydney, NSW, Australia; 4 Wako, Osaka, Japan; 5 Abcam, Sdonkey anti-mouse, Alexa 488 goat anti-mouse, Alexa 488
goat anti-rabbit, Alexa 488 goat anti-rat and Alexa 488
donkey anti-goat (Invitrogen, Life Technologies, Mulgrave,
VIC, Australia). All secondary antibodies were diluted in
PBS containing 1% BSA or 1% donkey serum (1:1,000 for
Alexa 555/594 and 1:600 for Alexa 488). Following 3× 5
minutes washes in PBS, the sections were incubated for 5
minutes in 4,6-diamidino-2-phenylindole (Invitrogen, Life
Technologies). All sections were mounted with Prolong
Gold Anti-Fade medium (Invitrogen, Life Technologies).
IgG-negative controls (mouse IgG2a and rat IgG2a; AbD
Serotec, Kidlington, UK) were used in place of primary
antibodies to give a measure of nonspecific background
staining. These IgG control antibodies were used at the
same concentrations as and were of the same species as
the primary antibodies listed above. Images were taken
with a Zeiss LSM Meta 510 upright confocal microscope
using a Plan-Apochromat 63× oil objective (Carl Zeiss Inc.,
Oberkochen, Germany).
Quantification of immunofluorescence for C1q and
C3b was performed on ~25 to 35 lumbar spinal cord
sections (per animal; n = 3) spaced 160 μm apart
and expressed as the percentage immunoreactive area
per section. Staining procedures and image exposures
were all standardised between genotype and between
sections.
Real-time quantitative PCR
Lumbar spinal cords from hSOD1G93A and WT mice
were collected into RNAlater (Ambion, Life Technologies)
and stored at −20°C for subsequent quantitative PCR
analysis. Total RNA was isolated using an RNeasy Lipid
Tissue extraction kit according to the manufacturer’s in-
structions (QIAGEN Inc, Alameda, CA, USA). After the
total RNA was purified using Turbo DNAse treatment
(Ambion, Life Technologies), cDNA was synthesised using
the Stratagene RT kit (Agilent Technologies Inc, Santa
Clara CA, USA). Commercially available gene-specific
TaqMan probes (Applied Biosystems, Life Technologies)try
Dilution In combination with
1:1,000 GFAP, Iba-1 and ChAT
1:50 GFAP, Iba-1 and ChAT
1:1,000 GFAP, CD11b, ChAT
1:250 GFAP, Iba-1, ChAT
1:1,000 C1q, C3b, C5, CD88
1:400 C1q, C3b and CD88
1:300 C5
1:100 C1q, C3b, C5, CD88
m-binding adapter molecule-1; 1 Hycult Biotechnology, Netherlands; 2 AbD
ydney, NSW, Australia; 6 Chemicon, Billerica, MA, USA.
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used are listed in Table 3. Relative target gene expression
to glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
was determined using the formula 2–ΔCT, where ΔCt = (Ct
target gene – Ct GAPDH) [19]. Final measures are pre-
sented as relative levels of gene expression in hSOD1G93A
mice compared with expression in WTcontrols.
Western blot analysis
Lumbar spinal homogenates from hSOD1G93A and WT
mice were resolved on a 10% SDS-PAGE gel and electro-
transferred onto nitrocellulose membranes. Membranes
were blocked in 2.5% skim-milk–Tris-buffered solution–
0.1% Tween 20 for CD88 and 5% BSA–Tris buffered
solution–0.1% Tween 20 for CD55 and were incubated
overnight with one of the following antibodies; anti-
CD88 (1:1,000; BMA Biomedical, Augst, Switzerland),
or anti-CD55 (1:1,000; Hycult Biotechnology). All pri-
mary antibodies were diluted in 5% BSA–Tris buff-
ered solution–0.1% Tween 20. Anti-CD88 was detected
with goat anti-chicken horseradish peroxidase (HRP)
(1:15,000; GE Healthcare, Pittsburgh, PA, USA) and
anti-CD55 was detected with goat anti-rat HRP (1:10,000;
GE Healthcare). These secondary antibodies were de-
tected by enhanced chemiluminescence (ECL; Amersham,
Pittsburgh, PA, USA). Blots were stripped and re-
probed with anti-GAPDH, (1:15,000; Millipore, Billerica,
MA, USA) and detected with sheep anti-mouse HRP
(1:4,000; GE Healthcare) to ensure equal protein loading.
Densitometric analyses of immunoreactive bands were
performed by deducting background pixels from the
grey-scale pixel density of the band multiplied by the
area value using Image J software [20]. The integrated
pixel value for each band was normalised to its corre-
sponding anti-GAPDH band. The normalised integrated
pixel values of hSOD1G93A bands were compared with WT
bands.Table 3 Taqman probes used for quantitative PCR










Mannose binding lectin 1 Mm00495413_m1
Mannose binding lectin 2 Mm00487623_m1In situ hybridisation
Synthesis of digoxigenin-labelled probes was performed
using digoxigenin RNA labelling mix according to
the manufacturer’s instructions (Roche, Brisbane, QLD,
Australia) using PCR-amplified cDNA templates generated
with primers specific for CD88: forward, TAATACG
ACTCACTATAGGGATCATCTACTCGGTGGTGTTCC
and reverse, AATTAACCCTCACTAAAGGGGAGAG
ACCTTAGGAGTCGTCCA. Lumbar spinal cords from
hSOD1G93A and WT mice were collected and fixed over-
night in 4% paraformaldehyde at 4°C. Samples were
processed and embedded in optimal cutting temperature
compound (Sakura Finetek), sectioned at 16 μm and
probed with CD88 riboprobes and sense control as previ-
ously described [21].
Enzyme-linked immunosorbent assay
Ninety-six-well plates (Greiner Bio-One, Frickenhausen,
Germany) were precoated with monoclonal rat anti-
mouse C5a capture antibody (Clone I52 – 1486; BD
Pharmingen, San Diego, CA, USA) diluted in coating
buffer (100 μM, NaHCO3, 34 μM Na2CO3, pH 9.5) over-
night at 4°C in a sealed humidified container. This cap-
ture antibody is specific for a neo-epitope exposed only
in mouse C5a/C5a desArg and does not cross-react with
C5 [22,23]. Following the plate being blocked for 1 hour
at room temperature with assay diluent (10% FCS/PBS),
C5a standard and lumbar spinal cord homogenates
was incubated for 2 hours at room temperature. The
plates were subsequently incubated with biotinylated
rat anti-mouse C5a detection antibody (clone I52-278;
BD Pharmingen) for 1 hour at room temperature, and
then incubated with streptavidin–HRP conjugate for
30 minutes at room temperature. Tetramethylbenzidine
(Sigma) substrate was used as the chromogen and the
plate was read at 450 nm. Levels of C5a in lumbar
spinal cord samples were adjusted to micrograms per
protein and expressed as nanograms of C5a per micro-
gram of protein.
Statistical analysis
All measures were performed using GraphPad Prism
5.0 (GraphPad Software Inc., San Diego, CA, USA).
The statistical differences between hSOD1G93A and WT
mice for body weight, Rota-rod test and hind-limb
grip strength test were analysed using a two-tailed
Student’s t test at each time point. For the results
from motor neuron counts, quantitative real-time PCR,
western blotting, ELISA, statistical differences between
hSOD1G93A and WT mice were analysed using a two-
tailed t test at each stage of disease progression. All
data are presented as mean ± standard error of the
mean and differences were considered significant when
P ≤0.05.
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Motor deficits in hSOD1G93A mice correlate with lumbar
motor neuron loss during disease progression
To monitor the decline in neuromotor performance and
loss of motor neurons during ALS progression in
hSOD1G93A mice, body weights, motor behavioural tests
and motor neuron counts were performed. The onset of
disease was defined as a stage in which a neuromotor
deficit was measurable. In this study, hSOD1G93A mice
showed a decrease in their body weight, hind-limb grip
strength and Rota-rod performance when compared with
WT mice. The weight of the hSOD1G93A mice reached the
maximum at 133 days of age and was significantly de-
creased when compared with WT mice at 140 days (mean
body weight, hSOD1G93A = 20.4 ± 0.23 g and WT = 22.3 ±
0.25 g, n = 9, *P < 0.05, #P < 0.001; arrow in Additional
file 1: Figure S1A).
The Rota-rod is a widely used measure of neuromotor
performance in hSOD1G93A mice [24]. In our study,
both hSOD1G93A and WT mice remained on the Rota-
rod for the full duration of the test until 119 days when
hSOD1G93A mice showed ~30% reduction in the time
remained on the Rota-rod (n = 12, *P < 0.05, #P < 0.001;
arrow in Additional file 1: Figure S1B). Next, we mea-
sured maximal hind-limb grip strength as an alternate
measure of neuromotor function [25,26]. At 70 days,
hSOD1G93A mice showed a significant reduction in grip
strength (~35% reduction; n = 12, *P <0.05, +P <0.01,
#P <0.001) when compared with WT mice (arrow in
Additional file 1: Figure S1C). Our results suggest that
the hind-limb grip strength test is a more sensitive meas-
ure of detecting motor deficit symptoms in hSOD1G93A
mice compared with weight loss and Rota-rod perform-
ance [26]. The Rota-rod test mainly evaluates balance and
coordination, and does not necessarily reflect muscle de-
nervation (that is, loss of muscle function [27]). By con-
trast, the decline in grip strength in the hSOD1G93A mice
closely correlated with the onset of lumbar motor neuron
loss at 70 days (n = 6, ***P <0.001; in Additional file 1:
Figure S1D). Post 70 days, we observed further declines
in hind-limb grip strength presumably resulting from a
progressive drop in lumbar motor neuron numbers up
to end stage (in Additional file 1: Figure S1C, D).
Components of the classical and alternate pathways
of complement are upregulated along with decreased
expression levels of complement regulators in
hSOD1G93A mice
Previous studies have identified various members of the
complement system that are upregulated in ALS and in
ALS animal models, but it is unclear which of the major
complement pathways are being activated. To investigate
this further, we examined the mRNA and protein levels
for some of the key initiators of the complement pathways,the classical, alternate and lectin pathways, as well as the
major complement regulators CD55 and CD59a [28].
The expression levels of initiating components of the
classical pathway (C1qB and C4), the alternative pathway
(factor B), the lectin pathway (mannose binding lectin 1
and 2), the central component common to all pathways,
C3, and the complement regulators CD55 and CD59a
were measured in the lumbar spinal cord of hSOD1G93A
mice during disease progression of ALS (30 to 175 days).
This was achieved using one of or a combination of the
following: quantitative real-time PCR, immunofluores-
cence and/or western blotting. C1qB and C4 transcripts
were significantly increased by 1.2-fold and 1.3-fold at
onset, 1.7-fold and 2.9-fold at mid-symptomatic disease,
and 13.1-fold and 10.7-fold by end stage of disease in
hSOD1G93A mice when compared with WT mice re-
spectively (n = 6, *P <0.05, **P <0.01 and ***P <0.001;
Figures 1A and 2D). Upregulation of C1q at end stage
was confirmed using immunofluorescence, where there
was marked increase in hSOD1G93A mice compared with
WT mice (Figure 1B). We also observed that the marked
increase of C1q in hSOD1G93A mice was localised to
motor neurons and activated microglia (white arrows
in Figure 1L, N (detailed in 1U), and white arrows in
Figure 1R, T (detailed in 1W)), compared with WT
where little to no C1q was observed (Figure 1C, D, E and
Figure 1I, J, K). We did not observe C1q on glial fibrillary
acidic protein (GFAP) expressing astrocytes in either
hSOD1G93A or WT mice (Figure 1O, P, Q (detailed in 1V)
for hSOD1G93A mice; Figure 1F, G, H for WT mice).
Factor B showed a similar activation profile to that of C1qB
and C4; namely, there was a 2.2-fold increase in mRNA at
mid-symptomatic disease, and by end stage of disease, there
was a 6.0-fold increase in hSOD1G93A mice respectively
compared with WT mice (n = 6, *P <0.05, ***P <0.001;
Figure 2E).
The central component of complement system C3 was
also increased in hSOD1G93A mice, but its expression
profile only dramatically increased by end stage in
hSOD1G93A mice when compared with WT. Specifically,
we observed 1.8-fold and 1.6-fold increases at onset and
mid-symptomatic disease, with a dramatic 10.2-fold in-
crease in C3 mRNA by end stage of disease when com-
pared with WT mice (n = 6, *P <0.05 and ***P <0.001;
Figure 3A). We then examined the expression and local-
isation of its activation fragment C3b in hSOD1G93A and
WT mice at end stage. Increased immunolabelling for
C3b was observed in the lumbar spinal cords of
hSOD1G93A mice compared with WT mice at end stage
(Figure 3B). In hSOD1G93A mice, C3b deposition appeared
primarily on motor neurons and microglia (white arrows in
Figure 3L, N (detailed in Figure 3U), and white arrows in
Figure 3R, T (detailed in Figure 3W) compared with WT,
where there was little to no C3b staining (Figure 3C, D, E,
Figure 1 Expression and localisation of C1q in hSOD1G93A and wild-type mice during disease progression. (A) mRNA expression profile of
C1qB in lumbar spinal cord of hSOD1G93A mice relative to wild-type (WT) mice. Dashed line, baseline expression in WT controls at each time point.
(B) Degree of immunolabelling for C1q significantly increased in the lumbar spinal cord of hSOD1G93A mice at end stage when compared with WT
mice. (A, B) Data expressed as mean ± standard error of the mean (n = 6 mice/group; *P <0.05, **P <0.01, ***P <0.001, Student t test). (C) to (T)
Double immunolabelling of C1q (red) with cellular markers (green) for motor neurons (ChAT; (C) to (E) WT mice, (L) to (N) hSOD1G93A mice),
astrocyte (glial fibrillary acidic protein (GFAP); (F) to (H) WT mice, (O) to (Q) hSOD1G93A mice), and microglia (Iba-1; (I) to (K) WT mice, (R) to (T)
hSOD1G93A mice) in the ventral lumbar spinal cord of WT and hSOD1G93A mice (end stage). There was minimal expression of C1q in WT (C, F and I)
with marked increase in hSOD1G93A mice (L, O and R). In hSOD1G93A mice, C1q was co-localised with ChAT-positive motor neurons (white arrows
in (L) and (N) (detailed in U)). There was little to no co-localisation of C1q with GFAP-positive astrocytes (Q (detailed in V)), and minimal co-localisation
with Iba-1-labelled microglia (white arrows in R and T (detailed in W)). PS, pre-symptomatic; OS, onset; MS, mid-symptomatic; ES, end-stage. Scale bar for
all panels = 20 μm.
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staining on GFAP expressing astrocytes in either hSODG39A
or WT mice (Figure 3O, P, Q (detailed in Figure 3V) for
hSOD1G93A mice and Figure 3F, G, H for WT mice).
Changes in mRNA expression level of mannose binding lec-
tin 1 and mannose binding lectin 2, which are the initiating
components of the lectin pathway, were not detectable in ei-
ther hSOD1G93A or WT mice (data not shown), suggesting
this pathway plays a minor role in this model.
The regulators of complement system CD55 and CD59a
were also investigated, because they are important in
maintaining homeostasis and keeping the complement sys-
tem in its proper physiological state. Specifically, CD55 and
CD59a negatively regulate complement activation by accel-
erating C3 convertase decay and inhibiting the assembly of
membrane attack complex respectively [29,30]. CD55mRNA expression was initially increased by 1.4-fold at pre-
symptomatic, and decreased at mid-symptomatic and end
stage of disease by 0.4-fold and 0.5-fold respectively when
compared with WT (n=6, *P <0.05 and ***P <0.001;
Figure 2A). This was confirmed at protein level using west-
ern blotting, where a 41 kDa CD55 immunoreactive band
was observed in all stages of hSOD1G93A mice and their re-
spective WT mice (Figure 2B, upper panel). Semi-
quantitative densitometry analyses of these bands with
respect to GAPDH loading controls (Figure 2B, lower
panel), revealed increased CD55 protein in the lumbar
spinal cord of hSOD1G93A mice by 3.2-fold at pre-
symptomatic and decreased by 0.7-fold at mid-
symptomatic and 0.6-fold at end stage respectively when
compared with WT mice (n = 4, *P <0.05 and ***P <0.001;
Figure 2C). CD59a mRNA was also increased initially at
Figure 2 Altered expression of complement components in hSOD1G93A and wild-type mice at different ages of disease progression.
(A) mRNA expression of CD55 in the lumbar spinal cord of hSOD1G93A transgenic mice relative to age-matched wild-type (WT) mice at four
different ages. (B) Representative western blot of CD55 with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in the lumbar spinal cord of
hSOD1G93A mice (SOD1) relative to age-matched WT mice, at different ages of disease progression. (C) Protein expression of CD55 determined by
semi-quantitative densitometry in the lumbar spinal cord of hSOD1G93A mice relative to age-matched WT mice at four different ages. (D) to (F)
mRNA expressions of C4 (classical pathway, D), factor B (alternative pathway, E) and CD59a (regulator, F) in lumbar spinal cord of hSOD1G93A
mice relative to age-matched WT mice at four different ages. (A, C, D, E, F) Dashed lines, baseline expressions in WT controls at each time point.
Data expressed as mean ± standard error of the mean (n = 6 mice/group; *P <0.05, **P <0.01, ***P <0.001, Student t test).
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0.2-fold when compared with WT mice (n = 6, *P <0.05
and **P <0.01; Figure 2F).
Collectively, the above results suggest that regulation of
complement system is perturbed, which leads to activation
of classical and alternate pathways of complement system
in the lumbar spinal cord of hSOD1G93A mice, which may
contribute to the disease progression of ALS.
C5 is expressed by motor neurons but is not altered
in hSOD1G93A mice
C5a, the ligand for CD88, is rapidly generated from its pre-
cursor protein C5 following complement activation [31].
We therefore examined the mRNA expression of C5 and
protein levels of C5a in hSOD1G93A and WT mice by quan-
titative real-time PCR and ELISA respectively. C5 mRNAexpression levels did not change in hSODG93A mice when
compared with WT mice over the four ages examined
(Figure 4A). Intriguingly, when we examined the protein ex-
pression levels of C5a we noted a steady decline in C5a
levels with increasing postnatal age in both hSOD1G93A and
WT mice; however, by disease end stage the levels of C5a
were significantly lower in hSOD1G93A mice when com-
pared with WT mice (n = 6, *P <0.05; Figure 4B).
Next, we immunostained lumbar spinal cords from
hSOD1G93A and WT mice for C5 with specific cellular
markers for motor neurons (anti-ChAT), astrocytes (anti-
GFAP), and microglia (anti-CD11b). C5 was clearly present
in ChAT-positive lumbar motor neurons from end-stage
hSOD1G93A and WT mice (white arrows in Figure 4C, D),
but not in GFAP-positive astrocytes (Figure 4E, F). For
microglia, we did not see any C5 in CD11b-positive
Figure 3 Localisation and expression of C3/C3b in hSOD1G93A and wild-type mice during disease progression. (A) mRNA expression
profile of C3 in lumbar spinal cord of hSOD1G93A mice relative to wild-type (WT) mice. Dashed line, baseline expression in WT controls at each
time point. (B) Degree of immunolabelling for C3b significantly increased in the lumbar spinal cord of hSOD1G93A mice at end stage when
compared with WT mice. (A, B) Data expressed as mean ± standard error of the mean (n = 6 mice/group; *P <0.05, **P <0.01, ***P <0.001,
Student t test). (C) to (T) Double immunolabelling of C3b (red) with cellular markers (green) for motor neurons (ChAT; (C) to (E) WT mice, (L) to
(N) hSOD1G93A mice), astrocyte (glial fibrillary acidic protein (GFAP); (F) to (H) WT mice, (O) to (Q) for hSOD1G93A mice), and microglia (Iba-1; (I) to
(K) WT mice, (R) to (T) hSOD1G93A mice) in the ventral lumbar spinal cord of WT and hSOD1G93A mice (end stage). C3b immunolabelling was
absent on motor neurons in WT mice (C to E), but was present on motor neurons in hSOD1G93A mice (white arrows in L and N (detailed in U)).
There was minimal co-localisation of C3b with Iba-1-labelled microglia in WT (white arrows in I and K). In hSOD1G93A mice immunolabelling of
C3b was evident in Iba-1-labelled microglia (white arrows, R and T (detailed in W)). There was no co-localisation with C3b and GFAP-positive
astrocytes in WT and hSOD1G93A mice (F to H for WT, O to Q (detailed on V) for hSOD1G93A mice). PS, pre-symptomatic; OS, onset; MS, mid-
symptomatic and ES, end-stage. Scale bars for all panels = 20 μM.
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some activated microglia (enlarged cell shape with thicken-
ing of proximal processes and decrease in ramification of
distal branches [32]) expressing low amounts of C5 in the
spinal cords from end-stage hSOD1G93A mice (white
arrows; Figure 4H).CD88 is upregulated during disease progression
in hSOD1G93A mice
Previous studies have shown an increase in CD88 expres-
sion in multiple rodent models of ALS [10,11]; hence this
study aimed to investigate whether there were similar
differences in expression of CD88 between hSOD1G93A
and WT mice during disease progression of ALS.The mRNA expression levels for CD88 in the lumbar
spinal cord of hSOD1G93A mice were normalised and com-
pared with WT mice during disease progression (30 to 175
days) using quantitative real-time PCR. CD88 expression
was increased by 2.3-fold at mid-symptomatic, and by 8.6-
fold at end stage of disease respectively compared with
WT mice (n = 6, *P <0.05 and ***P <0.001; Figure 5A). The
protein expression level of CD88 in the lumbar spinal
cords of hSOD1G93A and WT mice were measured using
western blotting. A 45 kDa CD88 immunoreactive band
was observed in all stages of hSOD1G93A mice and their
respective WT mice (Figure 5B, upper panel). Semi-
quantitative densitometry analyses of these bands with re-
spect to GAPDH loading controls (Figure 5B, lower panel)
revealed increased CD88 protein in the lumbar spinal cord
Figure 4 Expression and localisation of C5 and C5a in hSOD1G93A and wild-type mice during disease progression. (A) mRNA expression
profile of C5 in lumbar spinal cord of hSOD1G93A mice relative to wild-type (WT) mice. Dashed line, baseline expression in WT controls at each
time point. (B) Protein expression of C5a in the lumbar spinal cord of hSOD1G93A mice has decreased by end stage (ES) when compared with WT
mice. (A, B) Data expressed as mean ± standard error of the mean (n = 6 mice/group; *P <0.05, Student t test). (C) to (H) Double immunolabelling for C5
(red) with cellular makers (green) for motor neurons (ChAT; C and D, arrows), astrocytes (glial fibrillary acidic protein (GFAP), E and F), and microglia
(CD11b; G and H), in the ventral lumbar spinal cord region of hSOD1G93A mice (D, F and H) and WT mice (C, E and G) at end stage. Co-localisation of C5
with these cellular markers is seen as a merge of green and red (for example, white arrows in C, D, and H). PS, pre-symptomatic; OS, onset; MS,
mid-symptomatic; ES, end-stage. Scale bar for C to H = 20 μm.
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mid-symptomatic and end stage respectively when
compared with WT mice (n = 6, *P <0.05 and ***P <0.001;
Figure 5C).
CD88 is localised to motor neurons and activated
microglia with minimal localisation to astrocytes
in hSOD1G93A mice
Next, we aimed to determine the cellular localisation of
CD88 that has contributed to the increased expression
seen in hSOD1G93A mice. To achieve this, we performed
immunolabelling for CD88 on lumbar spinal cord sec-
tions from hSOD1G93A mice and WT mice. These sec-
tions were immunostained for CD88 and with specific
cellular markers to identify motor neurons (anti-ChAT),
microglia (anti-Iba-1) and astrocytes (anti-GFAP).
In WT mice, CD88 staining was observed on lumbar
motor neurons (Figure 5D). CD88-stained cells were
readily identified as motor neurons due to their large
size, location and distinctive morphology [17]. This was
confirmed by double-labelling with the motor neuron
marker ChAT (white arrows in Figure 5F). CD88 immu-
nostaining was localised predominantly to the motor
neurons’ soma (Figure 5D, E, F). To further support theseimmunohistochemical findings, we confirmed that motor
neurons expressed CD88 mRNA transcripts by in-situ hy-
bridisation (Figure 5D′, inset). Next, we examined whether
CD88 immunostaining was present on surrounding micro-
glia and astrocytes in sections of WT lumbar spinal cords.
We observed minimal co-localisation of CD88 to Iba-1-
positive microglia (white arrows in Figure 5G,I), but none
to GFAP-positive astrocytes (Figure 5J, K, L).
Following this demonstration of CD88 immunolabelling
in WT lumbar spinal cord, we then investigated CD88
cellular localisation in hSOD1G93A mice. CD88 was also
expressed on the few remaining motor neurons seen at the
end-stage of disease (white arrow in Figure 5O). By con-
trast to WT lumbar spinal cords, we observed prominent
CD88 immunostaining on other cellular structures sur-
rounding motor neurons in the lumbar spinal cords of
hSOD1G93A mice by the end stage of disease (for example,
yellow arrows in Figure 5M, O).
This additional CD88 immunoreactivity was investi-
gated in hSOD1G93A end-stage mice, using microglia
marker Iba-1 and astrocyte marker GFAP. By contrast to
Iba-1-positive microglia in WT mice, where these cells
expressed little observable CD88 and appeared to be
nonactivated (that is, small size with slender processes;
Figure 5 Expression and localisation of CD88 in hSOD1G93A and wild-type mice at four different ages. (A) mRNA expression of CD88 in
the lumbar spinal cord of hSOD1G93A mice relative to age-matched wild-type (WT) mice at four different ages. (B) Representative western blot of
CD88 with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in the lumbar spinal cord of hSOD1G93A (SOD1) mice relative to age-matched
WT mice at different ages. (C) Protein expression of CD88 determined by semi-quantitative densitometry in the lumbar spinal cord of hSOD1G93A
mice relative to age-matched WT mice at four different ages. (A), (C) Dashed lines, baseline expression in WT controls at each time point; data
expressed as mean ± standard error of the mean (n = 6 mice/group; *P <0.05, **P <0.01, ***P <0.001, Student t test). (D) to (U) Double
immunolabelling of CD88 (red) with cellular markers (green) for motor neurons (ChAT; (D) to (F) WT mice, (M) to (O) hSOD1G93A mice), microglia
(Iba-1; (G) to (I) WT mice, (P) to (R) hSOD1G93A mice), and astrocytes (glial fibrillary acidic protein (GFAP); (J) to (L) WT mice, (S) to (U) for
hSOD1G93A mice) in the ventral lumbar spinal cord of WT and hSOD1G93A mice at end stage. CD88 was co-localised with ChAT-positive motor
neurons (F, O, white arrows). (D′) CD88 mRNA transcript within lumbar motor neurons (determine by large cell size and location within the
ventral horn). In hSOD1G93A mice, immunolabelling of CD88 also evident on other cell types, indicated by lack of co-localisation with anti-ChAT
(yellow arrows in M and O). (G), (I) White arrows, small amount of CD88 staining within nonactivated microglia in WT mice, with increased CD88
expression on activated microglia in hSOD1G93A mice (P and R, white arrows). PS, pre-symptomatic; OS, onset; MS, mid-symptomatic; ES, end
stage. Scale bars for all panels = 20 μM.
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mice demonstrated an activated morphology with in-
creased expression of CD88 (white arrows in Figure 5P, R).
As expected, astrocytes were seen to increase in num-
bers as disease progressed in hSOD1G93A mice [33]. This
was noted by increased GFAP immunolabelling in the
lumbar spinal cord of hSOD1G93A mice at end stage
compared with WT mice (Figure 5K, L for WT, and
Figure 5T, U for hSOD1G93A mice). Minimal CD88 co-
localisation to GFAP-positive astrocytes was observed in
WT mice (Figure 5J, K, L) and at the end stage of disease
in hSOD1G93A mice (Figure 5S, T, U).
Discussion
While the pathogenesis of ALS is still unclear, there is
persuasive evidence that complement factors are in-
volved in promoting disease progression. Previous stud-
ies have demonstrated that C1q and C3 mRNA
expression are significantly increased during ALS pro-
gression in hSOD1G93A mice [4]. In addition,
upregulation of CD88 has also been observed in numer-
ous neurodegenerative diseases in rodents [34-37], in-
cluding ALS [10,11], so it is plausible to propose that
the complement system could be involved in the patho-
physiology of ALS. The present study demonstrates that
components of the classical and alternative complement
pathways are upregulated during the course of disease
progression in hSOD1G93A mice, and that C5a receptor
CD88 expression level is also increased. In addition, we
found a reduction in two major regulatory inhibitors of
complement activation as the disease worsened, which is
suggestive of a progressive dysregulation of complement
in this model. Furthermore, we show that C5, the pre-
cursor of C5a, is expressed predominantly by motor
neurons, suggesting that diseased motor neurons could
be a major source of C5a generation during disease pro-
gression. This local complement self-signalling in the
central nervous system might therefore contribute to
motor neuron death in hSOD1G93A mice as shown pre-
viously for cortical neurons [22]. Taken together, our re-
sults indicate that motor neurons may generate C5a
under stress, and that this may promote self-damage
under disease conditions that exist in ALS.
Classical and alternate complement pathways are
activated in ALS progression in hSOD1G93A mice
The present study provided evidence for the activation
of classical (C1qB and C4) and alternate (factor B) path-
ways of the complement system in the lumbar spinal
cord of hSOD1G93A mice during ALS disease progres-
sion. This is consistent with numerous studies in mouse
models of ALS and human patients where increased
levels of C1q, C3 and C4 have been found [4,38]. Further-
more this study also extended upregulation of C1qB andC3 mRNA expression in previous studies to protein levels
and localisation where C1q and C3b immunolabelling was
increased in hSOD1G93A mice and expressed on motor
neurons and microglia compared with WT. This may sug-
gest that upregulation of these components could assist in
the removal of dying motor neurons via opsonisation, dur-
ing disease progression in hSOD1G93A mice [39].
It is also possible that cell fragments or protein aggre-
gates from dying motor neurons could lead to comple-
ment activation in the degenerating spinal cord [28]. In
our study, complement activation was seen at disease on-
set (P70) and was restricted to the areas of motor neuron
death in the spinal cord of hSOD1G93A mice. Other studies
have demonstrated that complement components C1q
and C3b are located at the neuromuscular junction during
the early stages of disease (P47) in hSOD1G93A mice [40].
These findings are consistent with the idea that C1q and
C3b may contribute to the cellular destruction of motor
nerve terminals in these mice [41-43]. Taken together,
these findings and our own are consistent with the hypoth-
esis that the early loss of motor neuron terminals is
followed by the subsequent death of motor neurons within
the spinal cord. However, there is current debate about the
initiating site of degeneration in the cortical-motor system
(upper motor neurons [44]) versus peripheral (neuromus-
cular junction [41]). Future studies could contrast comple-
ment activation temporally at these different sites to
determine the initiating site of complement-mediated
neurodegeneration.
We also showed decreased mRNA expression levels
of complement regulators CD55 and CD59a at later
stages of the disease, which suggests that the homeo-
stasis of the complement system is perturbed, which
may lead to dysregulation and overactivation of the
complement system. This supports other studies,
which have shown that deficiency in CD55 and
CD59a exacerbates neuronal degeneration [45-47].
Our findings are also consistent with those of
Heurich and colleagues [40], where decreased (but
nonsignificant) levels of CD55 mRNA were observed
during the later stages of disease in hSOD1G93A mice.
In the present study, we also confirmed the mRNA
changes in CD55 at the protein level, which similarly
showed decreased CD55 levels at later stages of dis-
ease. Interestingly, we also observed an initial in-
crease in the mRNA expression levels of CD55 and
CD59a during early stages of disease. This may indicate
an early negative feedback mechanism to delay the
activation of complement in host cells, but this needs
further investigation.
Collectively, our data add further support to the no-
tion that complement activation may play an important
role in accelerating motor neuron loss and ultimately in
progression of ALS.
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neurons during disease progression
C5, the precursor of C5a, is expressed by motor neurons
in both WT and hSOD1G93A mice. This suggests that
motor neurons are a major source of C5 generation in
this tissue. We recently showed murine cortical neurons
also expressed endogenous C5, and generated C5a in re-
sponse to ischaemia, which contributed to neuronal cell
death [22]. It is plausible the same phenomenon is oc-
curring in the hSOD1G93A mouse, where stressed and
dying motor neurons generate their own C5a, to act in
an autocrine fashion by binding to CD88, present on
these neurons, to promote their death. Indeed, C5a has
been suggested to directly cause neuronal cell death in a
separate model of ALS [10]. C5a protein level in the
lumbar spinal cord only appeared to be significantly de-
creased by end stage in hSOD1G93A mice when com-
pared with WT mice. This could be due to fewer motor
neurons (a source of C5/C5a), and the increased CD88
receptor levels by surrounding activated microglia as
disease progressed. Increased CD88 on these cells would
act to internalise and degrade C5a post activation of its
receptor [48], which could account for the decline in
C5a levels over time. The consequence of C5a–CD88
signalling in WT motor neurons is not yet fully under-
stood and will need further investigation.
C5a receptor CD88 is upregulated during disease
progression in hSOD1G93A mice
The present study provided evidence for a patho-
physiological role of CD88 in hSOD1G93A mice. Specific-
ally, a significant increase in CD88 protein was observed
at mid-symptomatic and end stage in hSOD1G93A mice.
This is in agreement with our previous studies conducted
in hSOD1G93A rats [11]. The increase in CD88 pro-
tein in hSOD1G93A mice also parallels observations
in other models of neurodegenerative diseases, such as
Huntington’s disease and Alzheimer’s disease [35,36].
Taken together, this suggests that complement activa-
tion is a generalised response to neuronal injury in
neurodegenerative diseases. Furthermore, the ability of
CD88 antagonists to attenuate both neurodegeneration
and disease progression in rat models of ALS and
Huntington’s disease, and in mouse models of Alzheimer’s
disease, further suggests that increased CD88 activation ac-
tively contributes to neurodegeneration [11,37,49].
In addition to an increase in CD88 in hSOD1G93A
mice, the present study observed CD88 on motor neu-
rons in WT mice, as well as in hSOD1G93A mice. The
fact that CD88 was found on WT motor neurons sug-
gests that it may play a non-inflammatory role in motor
neuron function. Indeed, studies including our own,
have shown CD88 is also present on other neurons
within the brains of WT adult mice, including pyramidalneurons in the CA subfields of the hippocampus and
neocortex, and Purkinje cells in the cerebellum [50,51];
and CD88 has also been documented to be expressed on
human motor neurons [10]. Hence the physiological sig-
nificance of C5a receptor presence in motor neurons
awaits further study.
Previous studies have shown that motor neuron death in
animal models of ALS is exacerbated by toxic signals em-
anating from non-neuronal neighbouring cells (astrocytes
and microglia), via an inflammatory response that acceler-
ates disease progression [52,53]. The present study also
showed upregulation of CD88 on activated microglia, but
minimal expression on astrocytes in hSOD1G93A mice. The
latter is in contrast to our previous study conducted in
hSOD1G93A rats, where CD88 was expressed primarily on
proliferating astrocytes [11], but is in support of other
studies that show CD88 on microglia in other neurodegen-
erative diseases [36,54] The differential expression of CD88
on these proliferating glial cells between hSOD1G93A rat
and mouse models may suggest a differential role for
CD88 in these two species.
The strong co-localisation of CD88 with activated
microglia in hSOD1G93A mice suggests that CD88-
activated microglia contribute to the propagation of dis-
ease as opposed to the aetiology of the disease. This is
supported by previous studies where transplanted WT
microglia produced no delay of disease onset but sur-
vival was greatly extended through slowing of disease
progression in hSOD1G93A mice [55]. The exact mech-
anism by which C5a–CD88 signalling in microglia plays
a role in neurodegeneration is still unknown, but may
involve the release of reactive oxygen species through
NADPH oxidase, or proinflammatory cytokines, which
have been shown to be upregulated in ALS [56].
Conclusions
In summary, the present study has demonstrated the
upregulation of classical and alternative pathway com-
plement components, together with decreased levels
of complement regulators, suggesting that comple-
ment activation and/or its dysregulation may play an
important role in motor neuron loss and ultimately in
progression of ALS. Expression of C5a receptor CD88
was upregulated in hSOD1G93A mice, and the in-
creased expression of CD88 in end-stage hSOD1G93A
mice appears to be due to increased microglial CD88
expression. Taken together, these results indicate that
CD88 may play an important role in the pathophysiology
of ALS. These results pave the way for preliminary
pharmacological experiments using specific downstream
complement inhibitors in hSOD1G93A mice, such as C5
inhibitors or antagonists to C5a receptor that could con-
ceivably be extended to humans with positive therapeutic
outcomes.
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Additional file 1: Figure S1. Showing the decline in motor performance
during ALS progression correlates with lumbar motor neuron loss in the
lumbar spinal cord of hSOD1G93A mice. (A) Significant weight loss of
hSOD1G93A mice when compared with wild-type (WT) control mice at 140
days of age (arrow, n = 12, *P <0.05, #P <0.001, Student t test). (B), (C)
Significant reduction in time spent on Rota-rod and hind-limb grip strength
for hSOD1G93A versus WT mice, at 119 days and 70 days respectively (arrows,
n = 12, *P <0.05, +P <0.01, #P <0.001, Student t test). (D) Lumbar motor
neuron loss in hSOD1G93A mice when compared with WT control mice at 70
days of age onwards (n = 6, ***P <0.001, Student t test). The decline in motor
neuron number at 70 days correlates with the onset of loss of hind limb
muscle strength at this same age (C). Data expressed as mean ± standard
error of the mean. PS, pre-symptomatic (30 days postnatal (P30)); OS, onset
(70 days postnatal (P70)); MS, mid-symptomatic (130 days postnatal (P130));
ES, end-stage (175 days postnatal (P175)).
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